Charles Shi

Emory University IM Residency; aspiring GI oncologist

[Udhayvir Grewal @UGrewalMD]

Daraxonrasib is FDA approved! Big news! @PanCAN @TheGutOncLab

https://t.co/eC4CIO71J9

[Charles Shi @CShi321]

Grateful to have had the opportunity to work on this project under your strong mentorship @UGrewalMD and all the other great authors! Looking forward to working more in the NEN space!!

[Udhayvir Grewal @UGrewalMD]

Kudos to @EmoryDeptofMed resident @CShi321 for leading this comprehensive review on systemic therapies in gastroenteropancreatic neuroendocrine carcinomas in the European Journal of Cancer. GEP-NEC represents an incredibly heterogeneous and challenging disease to treat. Despite years of work, platinum chemotherapy regimens remain the mainstay of treatment (indeed a suboptimal standard of care), with select patients deriving benefit from targeted therapy and immune checkpoint inhibitors. Luckily there are newer agents (especially DLL3-targeting agents), that are currently in development and appear promising. @WinshipAtEmory @OncoThor @rohit_thum @Sarbaji85064063 @ChandrikhaC @helops79 🦓💊📈

Link: https://t.co/eiS5plTm0E

[Udhayvir Grewal @UGrewalMD]

Kudos to @EmoryDeptofMed resident @CShi321 for leading this comprehensive review on systemic therapies in gastroenteropancreatic neuroendocrine carcinomas in the European Journal of Cancer. GEP-NEC represents an incredibly heterogeneous and challenging disease to treat. Despite years of work, platinum chemotherapy regimens remain the mainstay of treatment (indeed a suboptimal standard of care), with select patients deriving benefit from targeted therapy and immune checkpoint inhibitors. Luckily there are newer agents (especially DLL3-targeting agents), that are currently in development and appear promising. @WinshipAtEmory @OncoThor @rohit_thum @Sarbaji85064063 @ChandrikhaC @helops79 🦓💊📈

Link: https://t.co/eiS5plTm0E

[Udhayvir Grewal @UGrewalMD]

Happy to share in print @OncJournal - Robust response to Pembrolizumab in a patient with metastatic VIPoma with acquired TMB-high/MSI-high phenotype post treatment with temozolomide.
Bottom line- in a patient with pancreatic or lung NET post exposure to temozolomide: always check liquid biopsy (or tissue if possible) and test for a hypermutated phenotype. In the presence of MSI-H disease or co-occurring DDR alterations, response to ICI can be durable and robust.

Kudos to @CShi321 @EmoryUniversity and my colleagues @PoHienEar @SethConcorsMD and others for helping put this together. @WinshipAtEmory @TheGutOncLab

https://t.co/kjzHTn6uPy

[American Osteopathic College of Radiology @AOCRNews]

Case courtesy of Charles Shi, MS II, Katherine Willer, DO | SUNY Upstate Medical University @UpstateRad

#radiology #AOCR #MedEd #RadRes #RadFellow #radiologist #radiologylearning #radiologylife #caseoftheweek